Patents Examined by Maria Leavitt
  • Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
    Patent number: 8877724
    Abstract: A therapeutically effective amount of an oligonucleotide is capable of influencing the properties and behavior of polymorphonuclear cells, e.g. suppressing endothelial adhesion and transmigration of said cells, and through this mechanism reduce the recruitment and/or migration of polymorphonuclear cells to a site of inflammation.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 4, 2014
    Assignee: Index Pharmaceuticals AB
    Inventors: Charlotte Admyre, Lars-Göran Axelsson, Oliver Von Stein, Arezou Zargari
  • Method for producing continuous cell lines
    Patent number: 8865450
    Abstract: The present invention relates to a method for production of continuous cell lines comprising providing living cells of an animal or a human, irradiating said cells with UV light, proliferating said cells and selecting multiplying cells as cells of a continuous cell line.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: October 21, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Manfred Reiter, Wolfgang Mundt, Simone Feigl, Simone Von Fircks
  • Use of Vgll3 activity modulator for the modulation of adipogenesis
    Patent number: 8852939
    Abstract: The present invention concerns Vgll3 a new target involved in adipogenesis modulation. Further, the present invention relates to methods to increase Vgll3 activity in adipocytes and preadipocytes. In addition, pharmaceutical composition comprising Vgll3 activity enhancing molecules in order to enhance the Vgll3 activity in a target tissue are also provided. These methods, compositions and molecules can be useful to modulate adipogenesis and thus treat obesity and related disorders.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: October 7, 2014
    Assignee: Sanofi
    Inventors: Diana Hall, Maria Jimenez, Carine Poussin, Bernard Thorens
  • Identification of a JAK2 mutation involved in vaquez polyglobulia
    Patent number: 8852931
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: October 7, 2014
    Assignees: Assitance Publique—Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Gustave-Roussy, Universite de Versailles—St Quentin en Yvelines, Universite Paris-Sud
    Inventors: William Vainchenker, Valérie Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall
  • Method for preparing human neoplastically transformed cells
    Patent number: 8846398
    Abstract: A method for preparing neoplastically transformed cells from human-derived cells, including the step of introducing human telomerase catalytic subunit (hTERT) gene, SV40 small T antigen (SV40ST) gene, and an antisense oligonucleotide derived from human 28S rRNA into the human-derived cells. The method for preparing neoplastically transformed cells from human-derived cells can be utilized when a variety of human normal cells are induced to be neoplastically transformed in order to elucidate cancer onset mechanisms, so that the method can be effectively utilized in search of target molecules for a new medicament.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 30, 2014
    Assignee: TRDIGM & Co., Ltd.
    Inventor: Katsutomo Hamada
  • Methods of improving stem cell homing and engraftment
    Patent number: 8846393
    Abstract: A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: September 30, 2014
    Assignee: Gamida-Cell Ltd.
    Inventor: Tony Peled
  • Lepidopteran insect N-acetylglucosaminidase genes and their use in glycoengineering
    Patent number: 8846886
    Abstract: A transgenic insect cell line for production of elevated levels of recombinant glycoproteins comprising mammalian-like N-glycans is provided. Also disclosed are nucleic acid sequences encoding ?-N-acetylglucosaminidases.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 30, 2014
    Assignee: University of Wyoming
    Inventors: Donald L. Jarvis, Christoph Geisler
  • Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
    Patent number: 8835359
    Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Ctla2b nucleic acid or Ctla2b protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: September 16, 2014
    Assignee: Sanofi
    Inventors: Mathias Gebauer, Martin Michaelis, Danping Ding-Pfennigdorff, Anke M. Schulte, Daniel Ziemek, Christiane Metz-Weldmann
  • Methods for detecting plasticizers
    Patent number: 8822384
    Abstract: Nanoparticles having one or more attached sensing moieties including uridine 5?-triphosphate (UTP) and deoxythymidine 5?-triphosphate (dTTP), are disclosed herein. These nanoparticles can, for example, be used for detection of plasticizers, such as phthalates, in the sample. Methods, kits and apparatuses using these nanoparticles for detecting plasticizers in a sample are also disclosed herein.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: September 2, 2014
    Assignee: East China University of Science and Technology
    Inventors: Bangce Ye, Min Zhang
  • Ecdysone receptor-based inducible gene expression system
    Patent number: 8822754
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: September 2, 2014
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Marianna Zinovjevna Kapitskaya, Dean Ervin Cress
  • Means and methods for counteracting, delaying and/or preventing adverse energy metabolism switches in heart disease
    Patent number: 8815822
    Abstract: The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: August 26, 2014
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Leon Johannes De Windt, Hamid El Azzouzi
  • Compositions for regenerating defective or absent myocardium
    Patent number: 8795728
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: August 5, 2014
    Assignee: CorMatrix Cardiovascular, Inc.
    Inventor: Robert G Matheny
  • Cell tissue gel containing collagen and hyaluronan
    Patent number: 8790683
    Abstract: A cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1 and uses thereof for stem cell delivery.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: July 29, 2014
    Assignee: National Cheng Kung University
    Inventor: Lynn L. H. Huang
  • Compositions for regenerating defective or absent myocardium
    Patent number: 8784891
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: July 22, 2014
    Assignee: CorMatrixCardiovascular, Inc.
    Inventor: Robert G Matheny
  • Methods and compositions for modulating peripheral immune function
    Patent number: 8785190
    Abstract: Disclosed herein are cell preparations useful for modulating various peripheral immune functions, methods for making said cell preparations, and methods for their use.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: July 22, 2014
    Assignee: SanBio, Inc.
    Inventors: Mo Dao, Casey C. Case
  • Sample lysis and coating of reaction surface
    Patent number: 8778842
    Abstract: The present invention provides copolymers that facilitate nucleic acid analysis, compositions that comprise such copolymers, and methods for making or using such copolymers.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: July 15, 2014
    Assignee: QIAGEN GmbH
    Inventors: Ralf Himmelreich, Roland Fabis, Christoph Erbacher, Sabine Werner, Bernd Springer
  • Compositions for regenerating defective or absent myocardium
    Patent number: 8771737
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: July 8, 2014
    Assignee: CorMatrix Cardiovascular, Inc
    Inventor: Robert G Matheny
  • Hepatitis C virus expressing reporter tagged NS5A protein
    Patent number: 8772022
    Abstract: Hepatitis C reporter viruses containing Core through NS2 of prototype isolates of all major HCV genotypes and the remaining genes of isolate JFH1, by insertion of reporter genes in domain III of HCV NS5A were developed. A deletion upstream of the inserted reporter gene sequence conferred favorable growth kinetics in Huh7.5 cells to these viruses. These reporter viruses can be used for high throughput analysis of drug and vaccine candidates as well as patient samples. JFH1-based intergenotypic recombinants with genotype specific homotypic 5?UTR, or heterotypic 5?UTR (either of genotype 1a (strain H77) or of genotype 3a (strain S52)) were also developed. The present inventors additionally developed J6/JFH1 recombinants with the 5?UTR of genotypes 1-6. These recombinants with different 5?UTRs are a useful to study the function of the 5?UTR in a genotype specific manner.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: July 8, 2014
    Assignees: Hvidovre Hospital, Kobenhavns Universitet
    Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Jens Bukh, Jannick Prento, Tanja Bertelsen Jensen, Jacob Bo Lademann, Yiping Li
  • Compositions and methods for osteogenic gene therapy
    Patent number: 8772571
    Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: July 8, 2014
    Assignees: The United States of America as represented by the Department of Veterans Affairs, Loma Linda University
    Inventors: Kin-Hing William Lau, David J. Baylink, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan
  • Oligonucleotide compound and method for treating nidovirus infections
    Patent number: 8759307
    Abstract: A method and oligonucleotide compound for inhibiting replication of a nidovirus in virus-infected animal cells are disclosed. The compound (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the infected cells, (iii) contains between 8-25 nucleotide bases, and (iv) has a sequence capable of disrupting base pairing between the transcriptional regulatory sequences in the 5? leader region of the positive-strand viral genome and negative-strand 3? subgenomic region. In practicing the method, infected cells are exposed to the compound in an amount effective to inhibit viral replication.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: June 24, 2014
    Assignees: Sarepta Therapeutics, Inc., The Scripps Research Institute
    Inventors: David A. Stein, Richard K. Bestwick, Patrick L. Iversen, Benjamin Neuman, Michael Buchmeier, Dwight D. Weller